Insider Buying: Veru Inc. (NASDAQ:VERU) Director Purchases 95,279 Shares of Stock

Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz bought 95,279 shares of Veru stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the transaction, the director now directly owns 195,279 shares in the company, valued at $107,403.45. This represents a 95.28 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Veru Stock Down 1.8 %

Shares of NASDAQ:VERU traded down $0.01 during trading on Thursday, hitting $0.59. The stock had a trading volume of 1,077,020 shares, compared to its average volume of 4,952,698. Veru Inc. has a 12-month low of $0.47 and a 12-month high of $1.92. The stock has a market capitalization of $86.22 million, a price-to-earnings ratio of -2.27 and a beta of -0.54. The stock has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $0.76.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. As a group, sell-side analysts forecast that Veru Inc. will post -0.22 earnings per share for the current year.

Wall Street Analyst Weigh In

VERU has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Veru in a report on Thursday, January 2nd. Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of Veru in a research note on Tuesday, November 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zacks Investment Management purchased a new position in shares of Veru during the 3rd quarter valued at about $25,000. Gladstone Institutional Advisory LLC grew its holdings in Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after acquiring an additional 14,500 shares during the period. SG Americas Securities LLC grew its holdings in Veru by 185.9% during the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after acquiring an additional 42,997 shares during the period. Weaver Consulting Group increased its holdings in shares of Veru by 41.0% during the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock valued at $45,000 after purchasing an additional 20,280 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Veru by 37.1% during the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock worth $49,000 after buying an additional 20,430 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.